Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 144,622

Document Document Title
WO/2021/092439A1
In certain embodiments, the present disclosure is directed to methods for treating depressive disorders in a human, wherein the methods comprise orally administering a therapeutically effective amount of N-[4-(6-fluoro-3,4-dihydro-1H-iso...  
WO/2021/090894A1
The present invention addresses the problem of providing a novel peptide capable of treating, preventing, or ameliorating a mood disorder. The present invention provides a peptide that has an amino acid sequence set forth in SEQ ID NO:...  
WO/2021/091281A1
The present invention relates to a technique for effective intranasal delivery to the brain. More specifically, the present invention is used for diagnosing, preventing or treating central nervous system encephalopathy, neurodegenerative...  
WO/2021/088317A1
Provided are an miRNA marker for the diagnosis and/or treatment of Alzheimer's disease. The miRNA marker is an miRNA-23 cluster. Also provided are the use of the microRNA of the miRNA-23 cluster in the diagnosis and/or treatment of Alzhe...  
WO/2021/091358A1
The present invention relates to a pharmaceutical composition for the prevention or treatment of a disease, disorder, or condition associated with Nurr1, including, as an active ingredient, a prostaglandin analog or a pharmaceutically ac...  
WO/2021/089824A1
The present invention relates to agonists of the 5-HT2Aserotonin receptors and their medical uses. In one aspect the invention relates to 5-HT2A agonists of formula (I). In another aspect, the invention relates to 5-HT2A agonists for use...  
WO/2021/091317A1
The present invention relates to synthetic α-secretase (SAS) and a use thereof. According to the present invention, a synthetic α-secretase, which is a fusion protein comprising, as an active ingredient, NIa protease, a fragment thereo...  
WO/2021/089873A1
The present invention relates to the synthesis of compounds of formula III from compounds of formula I via compounds of formula II. The present invention also relates to particular compounds of formula III, or pharmaceutically acceptable...  
WO/2021/088983A1
Disclosed is a 7,8-dihydroxyflavone composite nano-biomaterial with high bioavailability, a preparation method thereof, and an application thereof Specifically, the material uses zein and lactoferrin as packaging material and uses 7,8-di...  
WO/2021/088920A1
A nitrogen-containing ring derivative regulator, a preparation method therefor and use thereof. In particular, the present invention relates to a compound as represented by general formula (I), a preparation method therefor, a pharmaceut...  
WO/2021/089053A1
Disclosed is a nano complex for the targeted repairing of a neurovascular lesion. The nano complex comprises a lipid, an apolipoprotein and a targeted peptide, and the targeted peptide is formed by covalently linking, by means of a bridg...  
WO/2021/091316A1
The present invention relates to a composition, comprising TMEM176B as an active ingredient, for prevention or treatment of degenerative brain disease. A composition according to an embodiment promotes the phagocytic action of astrocytes...  
WO/2021/089790A1
The present invention relates to compounds having a lipid affinity of less than 15% by weight of the compound (such as a logP of -0.75 or less) for use in targeting mitochondria to reduce, inhibit or prevent the formation of mitochondria...  
WO/2021/088957A1
Disclosed are a novel aromatic heterocyclic compound as an ATX (Autotaxin) inhibitor, a pharmaceutical composition containing the compound, and a use of the compound and the composition in treatment of a disease having a pathological cha...  
WO/2021/071788A3
Among other things, the present disclosure provides C9orf72 oligonucleotides, compositions, and methods thereof. In some embodiments, the present disclosure provides methods for treating C9orf72-associated conditions, disorders or diseas...  
WO/2021/091585A1
The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof. The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, itch, and neurogenic inflammation.  
WO/2021/091474A1
The invention relates to selection of bacterial strain for use in treating serotonin deficiency and/or a disease related to serotonin deficiency by culturing bacteria of a lactic acid producing bacterial strain, under aerobic conditions,...  
WO/2021/092166A1
Methods of treating subjects having G4C2 dipeptide repeat expansion in the gene C90RF72, including subjects having amyotrophic lateral sclerosis or frontotemporal degeneration (ALS/FTD), are provided. Compounds directed at reducing the t...  
WO/2021/089769A1
The present invention relates to a compound of formula (I): for use in the treatment or prevention of neuroinflammation or an inflammatory brain disorder.  
WO/2021/091333A1
Disclosed are a microsphere capable of continuous drug release and a method for manufacturing same.  
WO/2021/090030A1
The disclosures herein relate to novel compounds of Formula (1): (1) and salts thereof, wherein R1, Q, X, Y and Z are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders asso...  
WO/2021/089683A1
The present application relates to novel substituted heterocyclic carboxamides, to processes for their preparation, to their use alone or in combinations for the treatment and/or prevention of diseases and to their use for producing medi...  
WO/2021/089781A1
The present invention relates to a compound of formula (I) for use in the treatment or prevention of a psychiatric brain disorder.  
WO/2021/089872A1
The present invention relates to compounds of formula I, or pharmaceutically acceptable salts thereof, as well as compositions comprising such compounds. These compounds and compositions have uses in the treatment of psychiatric or neuro...  
WO/2021/092096A1
Disclosed is an individualized dosing method of imaging the DAT receptors in a region of interest in the body of a subject using multiples of suboptimal packaging units of radiolabeled tracer, and kits for doing the same.  
WO/2021/089856A1
The present invention relates to modified adeno-associated virus (AAV) vectors for use in transducing a cell in the central nervous system (CNS) of a subject, and for use in the prevention or treatment of a CNS disease. In particular, th...  
WO/2021/092332A1
Disclosed are compositions engineered nanovesicles and compositions comprising CD38 inhibitors and methods of using said nanovesicles and compositions to treat an inflammatory liver disease as well as in inhibiting, reducing, or repairin...  
WO/2021/091381A1
A pharmaceutical liquid composition is provided comprising a solution of a physiologically acceptable salt of 4-phenylbutyric acid, preferably the sodium salt of 4-phenylbutyric acid, in an aqueous medium at a concentration of at least 1...  
WO/2021/088805A1
Disclosed in the present invention are compounds represented by structural formulas (I) and (II), a stereoisomer thereof or a pharmaceutically-acceptable salt thereof, a pharmaceutical composition containing the compounds, the stereoisom...  
WO/2021/044357A8
Compositions and devices comprising apomorphine or pharmaceutically acceptable salts are described. The compositions may comprise a solution of apomorphine, or a pharmaceutically acceptable salt thereof, and a propellant. The solution ma...  
WO/2021/091950A1
The disclosure provides polynucleotides containing SLC6A14 promoters, as well as vectors containing the same, that can be used to promote expression of a transgene in vestibular supporting cells. The polynucleotides described herein may ...  
WO/2021/089678A1
The present invention relates to improved medical therapies for all forms and stages of dementia involving administration of (i) GLP-1 receptor agonists to subjects with metabolic syndrome or (ii) semaglutide.  
WO/2020/092202A9
Featured are compositions comprising humanized and engineered variants of an antibody variable domain (e.g., FC5), chimeric molecules comprising same, compositions comprising same, and uses thereof.  
WO/2021/089300A1
The present invention relates to compounds 4-[5-[(rac)-1-[5-(3-Chlorophenyl)-3- isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine (TT00, TT001 and/or TT002), or a pharmaceutical composition comprising said TT00, TT001 and/or TT0...  
WO/2021/023069A8
Provided is an application of thiamine pyrophosphokinase TPK as a target in the treatment or prevention of Alzheimer's disease; using TPK as a target, brain TPK protein kinase activity or/and expression levels are promoted, preventing AD...  
WO/2021/092446A1
This disclosure describes a fentanyl hapten, a fentanyl hapten-carrier conjugate, methods of making the fentanyl hapten and the fentanyl hapten-carrier conjugate, and methods of using the fentanyl hapten and the fentanyl hapten-carrier c...  
WO/2021/091356A1
The present invention relates to a pharmaceutical composition, a functional food composition, and a cosmetic composition which include methyl benzoate or a derivative thereof as an active ingredient, and are for preventing or treating st...  
WO/2021/089768A2
The present invention relates to a compound of formula (I): for use in the treatment or prevention of a neurodegenerative disorder.  
WO/2021/089032A1
Disclosed are a compound as represented by general formula (I), a cis-trans isomer thereof, an enantiomer thereof, a diastereoisomer thereof, a racemate thereof, a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt...  
WO/2021/088758A1
The present invention belongs to the pharmaceutical field, and relates to an opioid receptor agonist, a preparation method therefor, and pharmaceutical use thereof. The present invention specifically relates to a 3-(dimethylaminomethyl)c...  
WO/2021/067611A3
The present disclosure features methods and compositions for treating Alzheimer's disease. The disclosed methods comprise administering to a subject having or suspected of having Alzheimer's a hematopoietic stem progenitor cell expressin...  
WO/2021/035289A9
This invention relates generally to therapeutic methods comprising the delivery of particular substituted pyridine based compounds for lowering intracranial pressure (ICP), in treating substance P mediated pathways in the brain such as, ...  
WO/2021/089776A1
The present invention relates to a compound of formula (I) for use in the treatment or prevention of a traumatic brain disorder.  
WO/2021/090911A1
Provided are: a method for selectively killing protein aggregate-containing cells; a kit therefor; a therapeutic drug for protein misfolding diseases; and a drug product for removing protein aggregates from a blood product. The method fo...  
WO/2021/067749A3
Provided herein are methods and compositions for reducing inflammation and/or treating osteoarthritis in a patient in need thereof. The methods includes administering to the patient an inhibitor of an inflammation amplifying (Inf-A) popu...  
WO/2021/090172A1
Therapeutic compositions comprising one or more agents that inhibit CXXC5-DVL interface and/or that enhance the activity of GLP-1, and methods of administering those therapeutic compositions to model, treat, reduce resistance to treatmen...  
WO/2021/087136A1
Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.  
WO/2021/085232A1
[Problem] Provided is a composition useful for treating and/or preventing neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease. [Solution] This composition is for treating and/or preventing neurodegenerative di...  
WO/2021/086966A1
Described herein are compounds represented by formula (I) or formula (la) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables R1, R2, R...  
WO/2021/085550A1
A fluorinated pyrimidine compound represented by general formula (1), (2), or (3). (In general formulas (1)-(3): R represents a C1-12 hydrocarbon group; X and Y each independently represent a hydrogen atom, a halogen atom, a C1-10 hydroc...  

Matches 1 - 50 out of 144,622